chrisvoncsefalvay/vaers-outcomes huggingface dataset:
PtcComplained of  having  increased heart rate . Assessment at the time presented the this V/S B/P 146/74, HR 145, Temp 98.7, RR18 Psox 98% RA. Pt. was offered water 500 ml which she finished. She was encouraged to stay for further observation . Pt's V/S @ 12:00 was Bp 122/74, HR96, RR14, Temp 98.7, Psox 99%RAPt left @ 12:05 p mand verbalized feeling a lot better/well.
This spontaneous report as received from a physician refers to a multiple, unspecified patients of unknown age and gender. There was no information about the patients concurrent conditions, concomitant therapies or medical history provided. On an unknown dates, the patients "might have been administered" an improperly stored doses of RECOMBIVAX HB (strength, dose, frequency, route of administration, lot # and expiration date were not reported). The storage temperature was 30 Fahrenheit degree for a 84 hours (7 cycles of 12 hours each cycle). There was an data logger. The products were back to range. No adverse effects were reported. Additional information has been requested.
Evening of shot (4-7) felt nausea, low grade fever (100.5), chills.  This lasted until around 3 AM on 4-9-21.  Had a little soreness and heat in shot arm.  Soreness in arm was pretty much gone by 4-10-21.  On morning of 4-10-21 pain in arm was pretty much gone , but noticed a strip about 2 in. long at shot site.  No discomfort from this.  On morning of 4-11-21 noticed that the redness had spread and had begun to itch.  By the end of the day 4-11 it had spread down my arm  and was about the size of my hand.  On morning of 4-12-21 it is still there and does not look like it has spread too much.  Still itches
Information has been received from a registered nurse concerning an 82 year old female with no medical history or no known allergies who on the morning of 9/7/05 was vaccinated IM in the right deltoid with the first dose of Pneumococcal 23v polysaccharide vaccine (lot 649111/0287P). There was no concomitant therapy or illness at the time of vaccination. The RN reported that on 9/7/05, the pt developed what was described as a possible allergic reaction. The pt was noted to have developed a red swollen arm. On 9/8/05, the patient went to the ER because her throat felt tight. The patient denied any allergies to the vaccine components. While in the ER, the pt was treated with two oral Benadryl tablets, was not admitted and was sent home. On 9/14/05 the pts events resolved. Additional information is not expected.
It started 3 days after being vaccine. I began to start getting red marks on my hips and it's by the size of a 5-cent piece. I start breaking out with hives and than I get the Shingles. My GP prescribes Valacyclovir each time I get the Shingles. I have gotten this each vaccines. I take it as needed.
Lightheaded feeling faint then blacked out and fell hitting my chin on a nightstand and dropped to the floor then getting extremely hot all over my bod then sweating profusely and extreme nausea
Itchy, burning rash beginning on hands, arms spreading to torso on Tues Sept 21st disappeared by noon the next day. On eve of 22nd, rash began again - very ill- whole body itch, face, legs red. Dr prescribed ALLEGRA - some relief found.
Patient seen on 12/21/11 for new onset right sided acute otitis media with fever. After patient left doctors office, had a flaccid febrile seizure.
Next day patient report fever/chills/swollen arm. Temp 102.5 on follow up 2-4-2015 patient reports the symptoms resolved with cold compress and time.
10 min. post-injection - developed soreness in 3rd & 4th digit of right hand, then entire left hand, and left foot.  Left hand and left foot soreness was resolved after 3 days, spontaneously.  Right 3rd & 4th digits soreness persist.  There is no neurological deficit of the involved digits.  1 day post-injection there was pain/heavy sensation in both arms.  These symptoms resolved on 3rd day post-injection.  However, the left arm pain returned on 12/21/04 and persist until today.  Current symptoms include right hand pain/soreness involving the 3rd & 4th fingers.  Patient unable to maintain grasp of a full cup of water.  Also mild but noticeable left arm pain.
Mild soreness at vaccination site; The patient received the third/booster dose of BNT162b2; This is a spontaneous report from a non-contactable consumer, the patient. A 53-year-old male patient received the third (booster) dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FH8030) via an unspecified route of administration in the left arm on 11Nov2021 at 17:00 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. Medical history included glaucoma. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included timolol maleate, brimonidine tartrate (COMBIGAN) and latanoprost, netarsudil mesilate (ROCKLATAN), both for an unknown indication from an unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3247) via an unspecified route of administration in the left arm on 09Mar2021 (at the age of 53-years-old) and also received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 01Apr2021 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. On 12Nov2021, the patient experienced mild soreness at vaccination site. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event mild soreness at vaccination site was resolved on an unknown date in Nov2021.   No follow-up attempts are possible. No further information is expected.
Vaccine expired on 10/27/21 or 8 days after we received it / second patient booster dose of .25ml; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine expired on 10/27/21 or 8 days after we received it / second patient booster dose of .25ml) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine expired on 10/27/21 or 8 days after we received it / second patient booster dose of .25ml). On 04-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Vaccine expired on 10/27/21 or 8 days after we received it / second patient booster dose of .25ml) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No Concomitant product use was reported. No treatment information was provided.  The patient received vaccine which was expired on 27-Oct-2021 or 8 days after the reporter received it. The patient did not have any adverse reactions.
Day of shot arm was sore and pain went away. 7-8 days after the injection (3 dose) the pain came back andmy arm hurt very badly. Couldn?t  lift the arm without significant pain.
Case number PHEH2014US024964, is an initial spontaneous report from a nurse received on 09 DEC 2014. This report refers to a 16- year-old male patient. Historical conditions were not reported. No concomitant medication was reported. The patient was vaccinated with FLUVIRIN 2014/2015 (batch number: 145701) intramuscularly at a dose of 0.5 ml on 28 OCT 2014. The  nurse reported that FLUVIRIN administered had 12 separate temperature excursions lasting for 30 minutes over a period of 34 days. The temperature excursion began on 16 OCT 2014 and the temperature was between 46 to 49 degree F during the excursion. No adverse event was reported following this maladministration (incorrect storage of drug). No further information was provided.
I believe that they were left in the freezer longer than the 14 days; This is a spontaneous report from a contactable pharmacist.     A patient of unspecified age and gender received bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 MRNA VACCINE; Solution for injection (Batch/Lot number was not reported), via an unspecified route of administration on an unspecified date as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant medications was not reported. During the call, stated, trying to follow up on a report that we sent on the vaccine just to make sure that these vials are still good because I believe that they were left in the freezer longer than the 14 days." Note: The patient's date of birth was not provided on the phone call. Note: The reporter's last name and address were not provided on the phone call. The reporter did not specify which vaccine. Pfizer-BioNTech COVID-19 Vaccine is being reported out of an abundance of caution. The following information was not confirmed during the call, but retrieved from the system: Reporter phone No. The following information was not provided during the call: Patient gender, Patient name. The outcome of the event was unknown.  Information about lot/batch number has been requested. Additional information has been requested.
arm soreness; fatigue; temperature of 99.0F; tingling sensation in her tongue; extreme lightheadedness; extreme dizziness; tingling sensation in her legs; tingling sensation in her mouth; This spontaneous case was reported by a consumer and describes the occurrence of DIZZINESS (extreme lightheadedness), DIZZINESS (extreme dizziness), PARAESTHESIA (tingling sensation in her legs), PARAESTHESIA ORAL (tingling sensation in her mouth) and PAIN IN EXTREMITY (arm soreness) in a 26-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 24-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Mar-2021, the patient experienced DIZZINESS (extreme lightheadedness), DIZZINESS (extreme dizziness), PARAESTHESIA (tingling sensation in her legs), PARAESTHESIA ORAL (tingling sensation in her mouth) and PARAESTHESIA ORAL (tingling sensation in her tongue). On 25-Mar-2021, the patient experienced PAIN IN EXTREMITY (arm soreness), FATIGUE (fatigue) and PYREXIA (temperature of 99.0F). On 24-Mar-2021, DIZZINESS (extreme lightheadedness) and DIZZINESS (extreme dizziness) had resolved. On 26-Mar-2021, PARAESTHESIA (tingling sensation in her legs), PARAESTHESIA ORAL (tingling sensation in her mouth), PAIN IN EXTREMITY (arm soreness), PARAESTHESIA ORAL (tingling sensation in her tongue), FATIGUE (fatigue) and PYREXIA (temperature of 99.0F) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 99.0 f 99.0 F.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment information was not provided.  The patient was also taking Skyla for birth control.
Arm swelled; This spontaneous case was reported by a patient family member or friend and describes the occurrence of PERIPHERAL SWELLING (Arm swelled) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Arm swelled). At the time of the report, PERIPHERAL SWELLING (Arm swelled) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant products were not provided.  Treatment medication were not reported.   This case was linked to MOD-2021-258739 (Patient Link).
Received Expired Dose; This spontaneous case was reported by a physician and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) in a 61-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 009c21a) for COVID-19 vaccination.     No Medical History information was reported.    On 10-Dec-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received Expired Dose). On 10-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Received Expired Dose) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication was reported. No treatment information was provided.   This case was linked to MOD-2021-418891 (Patient Link).
Information has been received from a foreign legal firm concerning an approx. 15 month old male with a history of croup at 12 months, who on 1/27/93 was vaccinated with his 1st dose of MMRII. Concomitant therapy included Hib conjugate vaccine in the right leg on 1/17/93. In approx. 1/93, the pt experienced autism, with initial symptoms of fever and irritability. At the mother's request, the child had been seen by an ENT surgeon because he had always drooled and was a mouth breather. His hearing was tested in 8/94 and was determined to be normal. The pt was referred to a speech therapist in July, 1994 and had been recently assessed by the therapist. The pt was evaluated by a physician with his mother and 4.5 year old brother, on 10/5/94, for behavior problems and speech delay. It was reported that the pt is the 2nd of 2 children. His father is a photographer and his mother is an ENT nurse. His mother had a normal pregnancy and the pt was born full term, with a birth weight of 8lbs. His motor milestones were normal, although he did not walk until approx. 14 or 15 months of age. During the evaluation, the pt's mother stated she was happy with the pt's development and that her main concern was with the pt's speech. The pt had a good vocabulary but did not put words together and missed the ending of the words. His gross motor function were normal and fine coordination was good. He was described as having poor listening skills, being overactive and agile and having no fear. He was able to concentrate when watching video and television. He attended playgroup 3 days a week and mixed well, but his teacher had to keep him under control because he tended to be quite active. It was reported that during the evaluation, the pt only cooperated in building a tower. He did not sit on the chair, climbed on the table, threw toys everywhere and did not concentrate. The assessment had to be abandoned due to his unacceptable behavior, attended playgroup 3 mornings a week. On 2/19/97, the pt received a booster shot of MMRII in the left leg (lot HC39880). Upon internal review, the pt's autism, fever, and irritability were considered "Other Medical Events". Additional information has been requested. Follow up information states that 2 weeks after injection, he developed a serious thirst.Within 6 months after the injection, approximately 7/93, it was reported that the pt's behaviour deterorated, he started to get constipated.He started vomiting, was not speaking a great deal. Within 9 months the pt's sleeping pattern was poor. He displayed obsessional behavior and started having temper tantrums. It was reported that in 1997, the pt had developed absence seizures. On 02/19/97 the pt received a booster of MMRII. The pt was diagnosed with autism in December 2000. Upon internal review, the pt's autism ans seizure were considered OMIC.
Muscle, tendon, joint aches, back ache; usually when I use my Valtrex, my symptoms go away within two days. I have had the symptoms for almost 2 weeks.
Patient only received the MenCYW-135 Liquid Conjugate Component of the vaccine.
This spontaneous report as received from a licensed practical nurse refers to over 40 unspecified patients of unknown age (no patient information provided). On an unknown date, the patient was vaccinated with, improperly stored outside temperature conditions listed in the product insert, GARDASIL (dosage regimen and indication were not provided). No adverse effects reported. The outcome of events was unknown. No product quality complaint (PQC) was involved. This is one of several reports received from the same reporter. Additional information has been requested.
I had extreme fatigue and a slight fever after receiving the vaccine. I didn't tend to my doctor after receiving the first dose; I took some ibuprofen and continued on. A year later, I received my booster shot (Pfizer: 01/05/2022; Lot Number: FL3198); a week after receiving my booster, I had a delayed reaction when my lips began feeling very dry and irritated and used Carmex to try moisturizing it. I went to look at my mouth and the inside of my lower lip were bright red, and I had a red line across my top lip. At the injection site of the vaccination, I had an open wound the size of a nickel. I went to my doctor on 01/24/2022 and gave me a 3-day regime of Prednisone to help with the irritation inside of my lip. The irritation and red line settled, but now I random irritation in my throat.
Patient immediately had severe nausea, diaphoretic, passed out briefly for a few seconds , had jerking of arms and then came back to consciousness. Ice was applied to back of neck, monitored vital signs through out visit. He said he felt nausea and tiredness, continued being diaphoretic, Vital signs taken again,  vitals stable.  Continued to rest under observation for 45 minutes. Vitals taken before leaving. Vitals stable. Patient denied sob,  swelling of tongue. No dizziness or light headedness. No cp.
Child was given a HEP A vaccine. Vaccine was not needed; child had completed the HEP A vaccine series 10 years ago. Nurse discussed with parent what had done and parent understood. Child had no reaction to the vaccine.
24 hours after immunization given, pt developed red warm area on right thigh that has increased in size since.
Information has been received from a registered nurse concerning an elementary aged child who was vaccinated with a dose of Varivax. The RN reported that in February  2006, the patient developed breakthrough chickenpox which was considered to be a light, mild case. Unspecified medical attention was sought. At the time of this report, the outcome was unknown. Additional information has been requested.
TROUBLE BREATHING; CAN'T STAND; CAN'T WALK; BRAIN FOG; STRONG ODOR IN THE URINE; CHEMICAL SMELL IN NOSE AND MOUTH; CHEMICAL TASTE IN NOSE AND MOUTH; BODY ACHE; SORE THROAT; LOOSING MEMORY; WEAKNESS; HEADACHE; This spontaneous report received from a patient concerned an 81 year old female. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine  (suspension for injection, route of admin not reported, batch number: 042A21A, and expiry: UNKNOWN) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 10-APR-2021, the subject experienced trouble breathing. On 10-APR-2021, the subject experienced can't stand. On 10-APR-2021, the subject experienced can't walk. On 10-APR-2021, the subject experienced brain fog. On 10-APR-2021, the subject experienced strong odor in the urine. On 10-APR-2021, the subject experienced chemical smell in nose and mouth. On 10-APR-2021, the subject experienced chemical taste in nose and mouth. On 10-APR-2021, the subject experienced body ache. On 10-APR-2021, the subject experienced sore throat. On 10-APR-2021, the subject experienced loosing memory. On 10-APR-2021, the subject experienced weakness. On 10-APR-2021, the subject experienced headache. The action taken with covid-19 vaccine  was not applicable. The patient recovered from trouble breathing, can't stand, can't walk, brain fog, strong odor in the urine, chemical smell in nose and mouth, chemical taste in nose and mouth, body ache, sore throat, loosing memory, and headache on MAY-2021, and had not recovered from weakness. This report was non-serious.
unable to work due to health issues; This is a spontaneous report from a Pfizer-sponsored program from a contactable other HCP.  A 79-years-old male patient received pneumococcal 13-val conj vac (dipht crm197 protein) (PREVNAR 13) (Lot#: 4908000), on 07Aug2020 at single dose for immunisation.  The patient medical history and the concomitant medications were not reported. The patient was unable to work due to health issues. The outcome was unknown.    No follow-up attempts are needed. No further information is expected.
Rt arm injection site hot to touch and swollen, cellulitis rt upper arm 2 hrs Izn reaction. Benadryl. Ice therapy, Advil for pain, rtc x 1 day to F/U daily.
Patient complained of having full body aches and joint paint (multiple joints affected: knees, ankles, toes, hands, wrist and elbows) and continued arthritis type symptoms.; Patient complained of having full body aches and joint paint (multiple joints affected: knees, ankles, toes, hands, wrist and elbows) and continued arthritis type symptoms.; Patient complained of having full body aches and joint paint (multiple joints affected: knees, ankles, toes, hands, wrist and elbows) and continued arthritis type symptoms.; Patient complained of having full body aches and joint paint (multiple joints affected: knees, ankles, toes, hands, wrist and elbows) and continued arthritis type symptoms.; This is a spontaneous report from a contactable consumer or other non-healthcare professional. This consumer reported for a 58-years-old male patient received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: Solution for injection, Batch/Lot number: not reported), via an unspecified route of administration on an unspecified date as a single dose for covid-19 immunisation. The patient medical history and concomitant medications were not reported. On an unknown date, patient complained of having full body aches and joint paint (multiple joints affected: knees, ankles, toes, hands, wrist and elbows) weeks after taking 2nd dose of COVID vaccine and continued arthritis type symptoms. It was reported that onset linked to after 2nd dose of vaccine and no other changes in diet, medications or physical exercise attributed to joint pain. Event took place after use of product. The outcome of event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.